Fangda advised AnHeart Therapeutics on the deal. Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...
Nuvation Bio’s Acquisition of Shares in AnHeart
Voneseals Technology’s Acquisition of a Stake in Shanghai Garnor Sealing Technology
Fangda Partners assisted Voneseals Technology (Shanghai) Inc. on the transaction. Voneseals Technology (Shanghai) Inc. completed the acquisition of a 51% equity stake in Shanghai Garnor Sealing Technology...
Anji Qicai Lingfeng Rural Tourism Investment’s Bonds Offering
DeHeng Hong Kong advised Anji Qicai Lingfeng Rural Tourism Investment Co., Ltd on the deal. Anji Qicai Lingfeng Rural Tourism Investment Co., Ltd completed the issuance...
Zhenjiang Culture & Broadcasting Industry Group’s Bonds Offering
DeHeng Law Offices (Hong Kong) LLP advised Zhenjiang Culture & Broadcasting Industry Group Co., Ltd. on the deal. Zhenjiang Culture & Broadcasting Industry Group completed the issuance of...
Jiangsu Aisen Semiconductor Material’s Listing on SEE STAR Market
Fangda advised Jiangsu Aisen Semiconductor Material on the deal. Jiangsu Aisen Semiconductor Material Co., Ltd. completed its successful listing on the STAR Market of the Shanghai...
Deutsche Bank’s CNY1 Billion Panda Bond
Norton Rose Fulbright and Fangda Partners advised Deutsche Bank Aktiengesellschaft on the issuance. Deutsche Bank Aktiengesellschaft completed the issuance of its second Panda bond with a volume...
Viva Biotech Holdings Group’s Investment Round
Fangda represented HLC on the deal. Viva Biotech Holdings Group completed the equity financing at both Viva Holdings and its subsidiary Viva Biotech (Shanghai) Ltd., bringing in...
Suzhou Sanegene Bio’s Collaboration Agreement with Hangzhou Zhongmei Huadong Pharmaceutical
Fangda advised SanegeneBio on the deal. Suzhou Sanegene Bio Inc. announced its strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of...
WuXi XDC Cayman’s Spinn off from WuXi Biologics
Fangda advised WuXi XDC Cayman Inc. on the deal. WuXi XDC Cayman Inc. successfully spun-off from WuXi Biologics (Cayman) Inc. for a separate listing on the Main...
Volkswagen’s CNY1.5 Billion Panda Bond Programme
Clifford Chance has advised leading automotive manufacturing company Volkswagen. Volkswagen completed the successful issuance of its first Panda bond with a volume of Renminbi 1.5 billion....
Arab Republic of Egypt’s Panda Bonds Offering
Fangda Partners represented the Arab Republic of Egypt on the deal. Arab Republic of Egypt completed the issuance of the three-year Renminbi-denominated sustainable development bonds in...
MultiMetaVerse’s Acquisition of Shanghai Shengran Information Technology
Fangda acted as legal counsel for MultiMetaVerse Holdings Limited. MultiMetaVerse Holdings Limited completed the acquisition of Taomee’s PRC entities, i.e., Shanghai Shengran Information Technology Co., Ltd....